InsidersTradesSigma
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Browse the full record of transactions filed by ANDERSON DANIEL GRIFFITH. Director active across 1 company, notably Sigilon Therapeutics, Inc.. Aggregated, 2 reports have been published. Split: 0 buy · 2 sells. Total volume traded: €3.3m. Activity tracked since 2 June 2021. The latest transaction was filed on 2 June 2021 (Cession). Regulator: SEC (Form 4). All data is accessible without signup.
2 of 2 declarations